Trial Profile
A Phase 1b Study to Assess the Safety, Antiviral Efficacy and Pharmacokinetics of PPI-461 in Patients With HCV Genotype-1 Infection.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Feb 2012
Price :
$35
*
At a glance
- Drugs PPI 461 (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 06 Nov 2011 Results were presented at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD).
- 02 May 2011 Actual end date (May 2011) added as reported by ClinicalTrials.gov.
- 02 May 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.